SR 33805

Drug Profile

SR 33805

Latest Information Update: 25 Jul 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi-Synthelabo
  • Class Cardiotonics; Indoles; Muscle relaxants; Sulfones; Vasodilators
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Heart failure; Hypertension

Most Recent Events

  • 25 Jul 1996 A comparative study with fantofarone has been added to the pharmacodynamics section
  • 12 Jun 1995 Discontinued-I for Atherosclerosis in European Union (Unknown route)
  • 12 Jun 1995 Discontinued-I for Heart failure in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top